Biodesix Inc BDSX.OQ BDSX.O is expected to show a rise in quarterly revenue when it reports results on November 3 for the period ending September 30 2025
The Louisville Colorado-based company is expected to report a 15.6% increase in revenue to $20.974 million from $18.15 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Biodesix Inc is for a loss of $1.44 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Biodesix Inc is $35.00, about 81.2% above its last closing price of $6.57
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -1.36 | -1.37 | -1.60 | Missed | -17.1 |
Mar. 31 2025 | -1.26 | -1.36 | -1.60 | Missed | -17.6 |
Dec. 31 2024 | -1.00 | -1.33 | -1.20 | Beat | 10 |
Sep. 30 2024 | -1.46 | -1.47 | -1.40 | Beat | 4.5 |
Jun. 30 2024 | -1.84 | -1.84 | -1.60 | Beat | 13 |
Mar. 31 2024 | -2.83 | -2.87 | -2.80 | Beat | 2.3 |
Dec. 31 2023 | -2.05 | -2.20 | -2.00 | Beat | 9.1 |
Sep. 30 2023 | -3.00 | -3.00 | -2.80 | Beat | 6.7 |
This summary was machine generated November 1 at 00:33 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments